



**ASX Announcement**

**7<sup>th</sup> August 2025**

**Atomo secures an order for Pascal worth US\$410,000 from Lumos**

- **Order comes after Lumos announces a significant agreement with PHASE Scientific for supply of the Pascal enabled FebriDx<sup>®</sup> test to the US market**

SYDNEY, Australia, 7<sup>th</sup> August 2025 - Atomo Diagnostics Limited (ASX:AT1) (Atomo) is pleased to announce that its strategic partner Lumos Diagnostics (ASX: LDX) (Lumos) has placed an order with the company for supply of US\$410,000 (A\$630,000) worth of Pascal cassettes to support scale up of FebriDx demand in the US market. The order from Lumos is the first since they secured an exclusive six-year U.S. distribution agreement for FebriDx<sup>®</sup> with PHASE Scientific last month.

The FebriDx<sup>®</sup> test, which utilises Atomo's patented Pascal test cassette to deliver improved usability and reliability in point of care settings, has already secured 510k clearance from the US FDA and is currently well progressed through a CLIA waiver study that is expected to be completed this month. Atomo is the exclusive licensor, manufacturer and supplier of the Pascal cassette to Lumos for its FebriDx product.

Lumos indicated that it expects the agreement with PHASE to generate FebriDx product sales of up to US\$316 million over the six-year term, assuming CLIA waiver is granted and contracted MOQ's achieved. With this agreement now in place, Atomo anticipates a significant increase in demand for its Pascal cassette in the US market.

Atomo Managing Director John Kelly said, *"We are very pleased to see demand for Pascal locked into a sizable long-term contract in the US market and stand ready to work with Lumos to support supply of Pascal into Lumos's supply chain and scale up of operations to meet demand for FebriDx."*

For personal use only



For more information, please contact:

John Kelly  
Atomo Diagnostics  
[john.kelly@atomodiagnosics.com](mailto:john.kelly@atomodiagnosics.com)  
Phone: +61 401 922 279

*This announcement was authorised by the Managing Director & CEO.*

### **About Atomo**

Atomo is an Australian headquartered medical device company supplying unique, integrated rapid diagnostic test (RDT) devices to the global diagnostic market.

Atomo's unique patented devices simplify testing procedures, enhance usability and improve reliability across rapid point-of-care (POC) and at-home testing applications. The Company has successfully commercialised a number of products across international markets and has supply agreements in place for testing applications targeting infectious diseases including HIV, Syphilis, viral vs bacterial differentiation, as well as the early detection of pregnancy.

See more at [www.atomodiagnosics.com](http://www.atomodiagnosics.com)